FIELD: biotechnology.
SUBSTANCE: shortened vWF variants are produced, connected with the Fc-part of immunoglobulin, capable to bind FVIII.
EFFECT: invention enables to facilitate the production and purification of FVIII, contributes to prolongation of the half-life of FVIII in blood.
12 cl, 11 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED VON WILLEBRAND FACTOR WITH PROLONGED HALF-CYCLE IN VIVO, USING IT AND METHODS FOR PREPARING | 2009 |
|
RU2528855C2 |
| USING OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | 2019 |
|
RU2803163C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| ISOLATED GLYCOPROTEIN IB ALPHA POLYPEPTIDE OF HUMAN THROMBOCYTES, FUSED PROTEIN, DNA MOLECULE (VERSIONS), EXPRESSION VECTOR (VERSIONS), CELL (VERSIONS), POLYPEPTIDE EXPRESSION METHOD, FUSED PROTEIN EXPRESSION METHOD, PHARMACEUTICAL COMPOSITION (VERSIONS), METHOD OF INHIBITING BODING OF BLOOD CELLS TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM, METHOD OF INHIBITING BONDING OF PROTEIN TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM AND DISORDER TREATMENT METHOD | 2004 |
|
RU2403262C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM | 2018 |
|
RU2819144C2 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| EXPRESSION PLASMID FOR HUMAN RECOMBINANT COAGULATION FACTOR VIII WITH DELETED B-DOMAIN IN CHO CELLS, CHO CELL PRODUCING HUMAN RECOMBINANT COAGULATION FACTOR VIII WITH DELETED B-DOMAIN, AND METHOD FOR PRODUCING ABOVE FACTOR | 2013 |
|
RU2561466C2 |
